Business
Novanta makes precision motion, photonics and medical technology components.
Novanta grew revenue, remained profitable, generated positive free cash flow at a 9.6% operating margin. Free cash flow declined, while inventory and stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 3.3%OK
- Profitability — Net income declined 16.0% to $53.829M from $64.087MWatch
- Cash flow — Free cash flow declined 65.7% to $48.429M from $141.35MWatch
- Margins — Operating margin contracted 206 bps to 9.59%Watch
- Accounting — Free cash flow declined, while inventory and stock compensation grew faster than revenueNote
- Insiders — 0 purchases and 15 salesWatch
Where the revenue comes from
Fiscal 2025, as NOVANTA INC reports it. History and quarterly detail are in the app.
- Robotics And Automation$318.6M
- Advanced Surgery$242.4M
- Precision Medicine$237.3M
- Precision Manufacturing$182.3M
Leadership changes
From NOVANTA INC's own filings, the day they're filed.
- Barbara Hulit · member · departureeff. 2025-11-01
- John Burke · Chief Accounting Officer · appointmenteff. 2024-08-22
- Peter Chang · Chief Accounting Officer · departureeff. 2024-08-22
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-09
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about NOVANTA INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.